Please assess the completion status of the following clinical trial:

Trial Title: Patient Registry of Intrathecal Ziconotide Management(PRIZM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age at the time of study entry.~* Patient who has severe chronic pain, whom IT therapy is warranted, and who is intolerant of, or refractory to other treatments, such as systemic analgesics, adjunctive therapies, and/or IT morphine.~* Patient is planned to be initiated on IT PRIALT as the sole agent in the pump at a participated site.~* Patient has not received PRIALT treatment administered continuously via Medtronic SynchroMed® II pump within the past 30 days.~* Patient has a life expectancy \>6 months as determined by the physician.~* Patient is able to read, understand, and voluntarily sign the IRB-approved informed consent document prior to the performance of any study-specific procedures.~* Patient is able to understand and complete required assessments.~Exclusion Criteria:~* Patient has a known hypersensitivity to PRIALT or any of its formulation components.~* Patient has a pre-existing history of psychosis.~* Patient has infection at the microinjection site, uncontrolled bleeding diathesis, or known spinal canal obstruction that impairs circulation of cerebrospinal fluid.~* Patient is being initiated with PRIALT in conjunction with other IT agents.~* Patients with any other concomitant treatment or medical condition that, in the opinion of the clinician, would render IT administration hazardous.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Severe Chronic Pain (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).